Longitude Capital amassed $385 million to invest in drug development and health technology for its second fund, Longitude Venture Partners II.

This firm’s first fund closed in July 2008 with $325 million. The portfolio contains mostly midstage to commercial-stage companies, including Amarin, Aptus Endosystems, AqueSys, CardioDx, Civitas Therapeutics, Corcept Therapeutics, Jazz Pharmaceuticals and NxStage Medical. It has offices in Menlo Park, Calif., and Greenwich, Conn. Read the press release.